The Fusion Protein of IFN-α and Apolipoprotein A-I Crosses the Blood–Brain Barrier by a Saturable Transport Mechanism

Abstract

IFN-α is widely used for the treatment of chronic viral hepatitis and malignancies. However, systemic IFN-α treatment causes severe neuropsychiatric complications in humans, including depression, anxiety, and cognitive impairments. We have previously reported that the fusion protein formed by IFN-α and apolipoprotein A-I (IA) circulates bound to high-density lipoproteins (HDLs) and exhibits liver targeting, increased half-life, enhanced immunostimulatory activity, and reduced cytotoxicity. As the transport of HDLs across the blood–brain barrier is a highly complex and regulated process, in this study, we examine the effects of IA on the brain. Determination of IFN-α in brain and serum after hydrodynamic administration of different doses of a plasmid encoding IFN-α or IA showed that IA penetrated into the brain by a saturable transport mechanism. Thus, at high serum levels of the transgenes, the induction of IFN-sensitive genes and the number of phospho-STAT1+ cell nuclei in the brain were substantially higher with IFN-α than with IA. This was associated with attenuation of neurodepression in mice given IA, as manifested by shorter immobility time in the tail suspension test. However, when given low doses of rIFN-α or the same antiviral units of HDLs containing IA, the induction of IFN-stimulated genes in the brain was significantly greater with the latter. In conclusion, IA crosses the blood–brain barrier not by diffusion, as is the case of IFN-α, but by a facilitated saturable transport mechanism. Thus, linkage to apolipoprotein A-I may serve to modulate the effects of IFN-α on the CNS.

The investigation of changes in proteins expression (Apolipoprotein A1 and albumin) in malignant astrocytoma brain tumor

“…Cholesterol acyltransferase is responsible for the formation of most cholesterol esters in plasma. [35] Apo A1 the major protein component of high-density lipoprotein (HDL). [36] Indeed, binding of HDL on hepatocyte membranes displayed two-binding sites with high and low affinities.…”

High-Density Lipoproteins and Cerebrovascular Integrity in Alzheimer’s Disease

“…Recently, BBB transport of plasmids encoding interferon alpha (IFNa) alone or fused to apoA-I was measured by examining the concentration of IFNa and its target genes in the brain following hydrodynamic infusion in mice. Fusion of IFNa to apoA-I changed its mode of transport into the brain from diffusion to a saturable mechanism independent of SR-BI (Fioravanti et al, 2012). Clearly, more research is needed to determine the mechanisms by which apoA-I enters the CNS.…”

Targeting low-density lipoprotein receptors with protein-only nanoparticles

“…A catalogue of potential BBB-crossing peptides and proteins for functionalization is available (Van et al, 2012) (Spencer and Verma, 2007b); ApoE (Re et al, 2011;Wagner et al, 2012) and Apo A-I (Fioravanti et al, 2012;Kratzer et al, 2007), have been already used to functionalize diverse types of drugs and nanoparticles to allow or enhance BBB crossing. Others, such as Kunitzderived peptides (Angiopeps), presented in plain protein-drug complexes, have entered…”